New Flagship startup aims to trailblaze ‘AI science factories’
A new Flagship Pioneering startup has emerged with $200 million and a team of experts in both science and AI to pursue what it calls “scientific superintelligence.” Lila Sciences, announced by ...
View ArticleVirtual physical therapy startup Hinge Health files to go public
Virtual physical therapy startup Hinge Health on Monday filed to go public, snapping a dry spell of digital health IPOs. Hinge treats musculoskeletal injuries and chronic pain remotely using software....
View ArticleBristol Myers buys out cell therapy partner 2seventy bio
Bristol Myers Squibb will acquire its CAR-T cell therapy collaborator 2seventy bio for $286 million in cash, the companies said late Monday evening. Bristol Myers and 2seventy have been longtime...
View ArticleArvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer...
Arvinas and Pfizer’s targeted protein degrader has not managed to distinguish itself from other, similar breast cancer drugs, according to pivotal data released Tuesday. Results of the Phase 3...
View ArticleDefine Ventures hires former Aetion CEO Carolyn Magill
Former Aetion CEO Carolyn Magill has joined digital health venture firm Define Ventures as a venture partner. It’s the third big hire for Define over the past year, after also bringing on industry...
View ArticleCorrected: Merck opens billion-dollar US facility to make Gardasil
Merck has opened a new manufacturing plant in Durham, NC which will make HPV vaccines, including its quadrivalent vaccine Gardasil and nine-valent vaccine Gardasil 9. The opening of the factory comes...
View ArticleEndo sells international business for $84M
Endo is selling its international pharmaceuticals business to Knight Therapeutics, a Montreal-based specialty pharma company. Endo will get $84 million upfront and could make another $15 million if...
View ArticleMineralys aims to raise $250M; Coherus discloses layoffs
Plus, news about BioNTech, Roche, Boehringer Ingelheim, CervoMed, Genmab, Inozyme Pharma, Valo Therapeutics and Agomab: Mineralys Therapeutics’ $250M follow-on offering: Stellar Phase 3 data for the...
View ArticleWalgreens turns on dark mode
After months of reports that Walgreens was looking to go private, the retail pharmacy giant (to some folks’ surprise) managed to pull off a deal. The $10 billion transaction with ...
View ArticleGilead plans to skip from Phase 1 to Phase 3 with once-yearly PrEP drug
Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage study with a small group of healthy participants. The drugmaker is now planning...
View ArticleMerck dodges ‘failure to warn’ claims in federal Gardasil cases
Merck convinced a federal judge to toss claims alleging that it failed to properly warn patients of potential risks related to its Gardasil HPV vaccine. District Judge Kenneth Bell in North Carolina...
View ArticleFDA review departments largely spared from Musk-led cuts
Since President Trump took office, Elon Musk's Department of Government Efficiency has laid off thousands of government workers through broad, sudden cuts — some later reversed — that have thrown the...
View ArticleUpdated: Zealand partners with Roche on its amylin analog in a deal worth up...
Zealand Pharma has finally found a partner. And according to the Danish company, the licensing deal it announced with Roche on Wednesday for its amylin analog petrelintide is the biggest ever for an...
View ArticleOno licenses rare blood disease drug from Ionis for $280M upfront
Ono Pharmaceutical is spending $280 million upfront to take the global rights of Ionis Pharmaceuticals’ asset for a rare blood disorder, marking the latest partnership for a disease space that has...
View ArticleLegend to double Carvykti production as it targets blockbuster status
Unlocking manufacturing capacity will be key for Legend Biotech and Johnson and Johnson in achieving their goal of reaching “blockbuster status” for Carvykti in 2025, Legend CEO Ying Huang said. The...
View ArticleViking Therapeutics taps CordenPharma to manufacture its obesity drugs
Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor agonist for weight loss. The Swiss CDMO will...
View ArticleInsilico nabs $110M Series E for AI drug discovery after stalling Hong Kong...
Insilico Medicine, part of the first wave of AI-driven drug discovery and development shops, secured a $110 million megaround at a unicorn valuation for its pipeline of 30 treatment candidates. The...
View ArticleAscletis’ not-so-great weight loss data; Vivace’s $35M Series D
Plus, news about Harbour BioMed: Ascletis’ muscle-preserving drug yields limp weight loss data: The Hong Kong-based biotech said its adipose-targeted obesity therapy, called ASC47, demonstrated...
View Article#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks...
Here are some of the most compelling HIV updates from the annual Conference on Retroviruses and Opportunistic Infections in San Francisco: Merck details Phase 3 wins for two-drug regimen Merck
View ArticleWhy Gilead could lose its HIV product hopping case
Can Gilead be held accountable for holding back the sale of an HIV drug it allegedly knew was safer than its blockbuster predecessor? That's the question before the California Supreme Court, and the...
View Article